Firma Chun Cheong
Concise Prescribing Info
Prevention (tab) & treatment (infusion) of ischaemic neurological deficit following aneurysmal subarachnoid haemorrhage.
Dosage/Direction for Use
Tab Adult Prophylaxis 2 tab 4-hrly (360 mg daily). Start w/in 4 days of subarachnoid haemorrhage onset & continued for 21 days. Infusion Treatment Start infusion w/ 1 mg/hr (about 15 mcg/kg/hr) for 2 hr. Increase dose to 2 mg/hr (about 30 mcg/kg/hr) after the 2nd hr. Begin treatment as early as possible after neurological deficit, continue for at least 5 days up to a max of 14 days. Patients weighing <70 kg or w/ unstable BP Start dose w/ 0.5 mg/hr or less if necessary.
May be taken with or without food: Take consistently, either always w/ or always w/o meals. Swallow whole, do not chew/crush.
Hypersensitivity. Tab: Concomitant administration w/ rifampicin; antiepileptic drugs (eg, phenobarb, phenytoin or carbamazepine).
Special Precautions
Close monitoring is recommended in case of elevated intracranial pressure or generalized cerebral edema. Use cautiously in patients w/ hypotension. Patients w/ unstable angina or w/in 1st 4 wk after acute MI. May impair sperm function. Pregnancy & lactation. Tab: Co-administration w/ CYP3A4 inhibitors & inducers. Infusion: Contains 23.7% ethanol.
Adverse Reactions
Thrombocytopenia; allergic reaction, rash; headache; tachycardia; hypotension, vasodilatation; nausea. Infusion: Inj & infusion site reactions (eg, thrombophlebitis).
Drug Interactions
Increased plasma conc w/ fluoxetine. Slightly decreased exposure w/ nortriptyline. Increased effects of anti-hypertensives [eg, diuretics, β-blockers, ACE inhibitors, other Ca antagonists, α-adrenergic blocking agents (eg, α1-antagonists), PDE5 inhibitors, α-methyldopa]. Tab: Reduced efficacy w/ rifampicin. Reduced bioavailability w/ CYP3A4-inducing anti-epileptic drugs (eg, phenobarb, phenytoin or carbamazepine). Potential increased plasma conc w/ macrolide antibiotics (eg, erythromycin); anti-HIV PIs (eg, ritonavir); azole anti-mycotics (eg, ketoconazole); nefazodone; quinupristin/dalfopristin; cimetidine; valproic acid; grapefruit juice. Infusion: Mutual potentiation of negative ionotropic action w/ simultaneous IV administration of β-blockers. Renal function deterioration w/ aminoglycosides, cephalosporins, furosemide. Increased AUC of zidovudine IV.
MIMS Class
Nootropics & Neurotonics/Neurotrophics / Peripheral Vasodilators & Cerebral Activators
ATC Classification
C08CA06 - nimodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Nimotop infusion solution 10 mg/50 mL
5 × 1's
Nimotop tab 30 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in